UY38949A - Moléculas de unión a antígeno de multidireccionamiento para su uso en enfermedades proliferativas - Google Patents

Moléculas de unión a antígeno de multidireccionamiento para su uso en enfermedades proliferativas

Info

Publication number
UY38949A
UY38949A UY0001038949A UY38949A UY38949A UY 38949 A UY38949 A UY 38949A UY 0001038949 A UY0001038949 A UY 0001038949A UY 38949 A UY38949 A UY 38949A UY 38949 A UY38949 A UY 38949A
Authority
UY
Uruguay
Prior art keywords
binding
binding molecules
domain
proliferative diseases
targeting antigen
Prior art date
Application number
UY0001038949A
Other languages
English (en)
Inventor
Tara Arvedson
Tobias Raum
Christoph Dahlhoff
Julie Bailis
Jonas Anlahr
Matthew Chun
Igor D'angelo
Stephanie Everts
Matthias Friedrich
Lars Gaedtke
Rebecca Goldstein
Jonas Karl-Josef Honer
Roman Kischel
Matthias Klinger
Peter Kufer
Markus Muenz
Virginie Naegele
Marc Panzer
Doris Rau
Ines Ullrich
Patrick Hoffmann
Original Assignee
Amgen Inc
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Amgen Res Munich Gmbh filed Critical Amgen Inc
Publication of UY38949A publication Critical patent/UY38949A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona moléculas de unión a antígeno biespecíficas caracterizadas por comprender un primer y un segundo dominio de unión, que se une cada uno a CS1, BCMA, CD20, CD22, FLT3, CD123, CLL1, MSLN, CDH3 o EpCAM, un tercer dominio que se une a un epítopo extracelular de la cadena CD3e humana y de Macaca y opcionalmente un cuarto dominio, que está en una modalidad Fc. Además, la invención proporciona un polinucleótido, que codifica la molécula de unión a antígeno, un vector que comprende este polinucleótido, células hospedadoras que expresan la construcción y una composición farmacéutica que comprende la misma.
UY0001038949A 2019-11-06 2020-11-06 Moléculas de unión a antígeno de multidireccionamiento para su uso en enfermedades proliferativas UY38949A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962931783P 2019-11-06 2019-11-06
US201962953120P 2019-12-23 2019-12-23

Publications (1)

Publication Number Publication Date
UY38949A true UY38949A (es) 2022-09-30

Family

ID=73642849

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038949A UY38949A (es) 2019-11-06 2020-11-06 Moléculas de unión a antígeno de multidireccionamiento para su uso en enfermedades proliferativas

Country Status (9)

Country Link
US (1) US20220403035A1 (es)
EP (1) EP4055050A2 (es)
JP (1) JP2023500869A (es)
AU (1) AU2020377483A1 (es)
CA (1) CA3158604A1 (es)
MX (1) MX2022005417A (es)
TW (1) TW202136300A (es)
UY (1) UY38949A (es)
WO (1) WO2021089748A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022505921A (ja) * 2018-10-26 2022-01-14 カファ セラピューティクス リミテッド Ｃｌｌ１を標的とする抗体およびその応用
WO2023039243A2 (en) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ581395A (en) * 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP3148580B1 (en) * 2014-05-29 2021-01-20 MacroGenics, Inc. Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
ES2889906T3 (es) * 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
MA43955B1 (fr) * 2016-02-03 2022-02-28 Amgen Inc Anticorps anti-bcma et anti-cd3 bispécifiques de format bite
CA3095093A1 (en) * 2018-04-05 2019-10-10 Novartis Ag Trispecific binding molecules against cancers and uses thereof

Also Published As

Publication number Publication date
AU2020377483A1 (en) 2022-05-26
MX2022005417A (es) 2022-05-26
WO2021089748A3 (en) 2021-09-02
US20220403035A1 (en) 2022-12-22
EP4055050A2 (en) 2022-09-14
JP2023500869A (ja) 2023-01-11
CA3158604A1 (en) 2021-05-14
WO2021089748A9 (en) 2021-07-29
TW202136300A (zh) 2021-10-01
WO2021089748A2 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
BR112018015670A2 (pt) construtos de anticorpo biespecíficos envolvendo células t
BR112018015715A2 (pt) construtos de anticorpo de engate de célula t biespecífica bcma e cd3
CL2020003416A1 (es) Constructos de anticuerpo biespecificos que se unen a mesotelina y cd3 (divisional sol. 201800268)
EA201891753A1 (ru) Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
CL2019002717A1 (es) Receptores de unión a antígeno mejorados.
PE20181013A1 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
PE20181152A1 (es) Constructos de anticuerpo biespecificos que se unen a dll3 ycd3
PE20170772A1 (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de union a antigeno, una composicion farmaceutica y uso
CL2017002641A1 (es) Construcciones de anticuerpos biespecíficos contra cdh3 y cd3
BR112016022841A8 (pt) Anticorpo igm, iga, igg / igm ou igg / iga, ou um fragmento de ligação ao antígeno do mesmo, composição que o compreende e uso do mesmo
UY38949A (es) Moléculas de unión a antígeno de multidireccionamiento para su uso en enfermedades proliferativas
UY38041A (es) Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
MX2021000392A (es) Anticuerpos anti-mesotelina.
PH12019500802A1 (en) Antibodies that bind zika virus envelope protein and uses thereof
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
MX2021003756A (es) Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos.
AR114069A1 (es) Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
EA202091600A1 (ru) Конструкция на основе биспецифического антитела, направленная на muc17 и cd3
AR105558A1 (es) Constructos de anticuerpo para dll3 y cd3
AR105560A1 (es) Constructos de anticuerpo para msln y cd3
AR105562A1 (es) Constructos de anticuerpo para receptor del factor de crecimiento epidérmico variante viii (egfrviii) y el antígeno cd3